Cancer and the microbiome: from association to intervention.

Higher microbial diversity and immunostimulatory pathways in the gut microbiome are linked to improved immune checkpoint inhibitor responses in cancer patients.

• Why it matters: Understanding how the microbiome influences cancer therapy outcomes can lead to more effective treatments and personalized approaches, addressing current gaps in optimizing immunotherapy.
• What they did: The authors reviewed existing evidence from studies involving melanoma, lung, and kidney cancers, and examined microbiome-targeted interventions like fecal transplants, diet, and probiotics, currently in clinical trials.
• The result: Findings suggest that modulating the microbiome could enhance treatment efficacy, but interventions are still experimental, and challenges remain in translating these insights into standard care.